Candel Therapeutics (NASDAQ:CADL) Now Covered by Analysts at Citigroup
Citigroup started coverage on shares of Candel Therapeutics (NASDAQ:CADL – Free Report) in a research report released on Thursday morning, MarketBeat reports. The firm issued a buy rating and a $25.00 price target on the stock. A number of other equities research analysts also recently commented on the company. Bank of America started coverage on […]
Citigroup started coverage on shares of Candel Therapeutics (NASDAQ:CADL – Free Report) in a research report released on Thursday morning, MarketBeat reports. The firm issued a buy rating and a $25.00 price target on the stock. A number of other equities research analysts also recently commented on the company. Bank of America started coverage on […]
